Actavis Inc (ACT)
125.44USD
1 Jul 2013
$-0.78 (-0.62%)
$126.22
$126.63
$127.62
$125.13
1,406,260
1,660,872
$133.00
$73.39
ACT
About
Overall
| Beta: | 0.36 |
| Market Cap (Mil.): | $16,721.81 |
| Shares Outstanding (Mil.): | 133.31 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ACT | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 32.92 | 33.02 |
| EPS (TTM): | -0.47 | -- | -- |
| ROI: | -0.73 | 19.76 | 19.07 |
| ROE: | -1.66 | 20.57 | 20.00 |
U.S. justices say FTC can challenge deals to keep generic drugs off market
WASHINGTON, June 17 - The U.S. Supreme Court ruled on Monday that the Federal Trade Commission can challenge deals that brand-name drug companies make with generic rivals to keep cheaper products off the market.
PRESS DIGEST - Financial Times - May 21
Essar Oil to sign fuel-for-cash deal with China Development Bank
Actavis to buy Warner Chilcott in $5 billion stock deal
- Generic drugmaker Actavis Inc, itself a recent takeover target, said on Monday it would buy specialty pharmaceutical company Warner Chilcott Plc for $5 billion in stock to expand its branded drug portfolio, lower taxes and increase profits.
UPDATE 4-Actavis to buy Warner Chilcott in $5 billion stock deal
May 20 - Generic drugmaker Actavis Inc, itself a recent takeover target, said on Monday it would buy specialty pharmaceutical company Warner Chilcott Plc for $5 billion in stock to expand its branded drug portfolio, lower taxes and increase profits.
CORRECTED-UPDATE 1-Actavis to buy Warner Chilcott in $5 billion stock deal
(Corrects to show deal value of $5 billion, not $8.5 billion)
US STOCKS-Futures little changed after records, acquisitions eyed
* Actavis to acquire Warner Chilcott in stock-for-stock deal
Actavis to buy Warner Chilcott in $8.5 bln deal
May 20 - Generic drugmaker Actavis Inc will buy specialty pharmaceuticals company Warner Chilcott Plc in a stock deal valued at about $8.5 billion.
BRIEF-Actavis says to buy Warner Chilcott for $8.5 bln
May 20 - Actavis Inc : * Recommended offer for Warner Chilcott by Actavis * Will acquire Warner Chilcott Plc in a stock-for-stock transaction valued at
Warner Chilcott buy may be Actavis' best takeover defense
NEW YORK - Generic drugmaker Actavis , the subject of intense takeover speculation, may have found its best defense: a potential purchase of Warner Chilcott Plc , a specialty pharmaceutical company that has been for sale on and off for years.
Novartis says has no intention of buying Actavis
ZURICH - Novartis has no plans to bid for U.S.-based generic drugmaker Actavis, which is the subject of intense takeover speculation, a spokesman for the Swiss drugmaker said on Thursday.
Competitors
| Price | Change | |
|---|---|---|
| McKesson Corporation (MCK.N) | $116.18 | +1.68 |
| Cardinal Health Inc (CAH.N) | $47.59 | +0.39 |
| AmerisourceBergen Corp. (ABC.N) | $55.01 | -0.82 |
| Novartis AG (NOVN.VX) | CHF67.15 | -0.15 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 14,190.00₪ | +60.00 |
| Mylan Inc. (MYL.OQ) | $30.86 | -0.17 |
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
